Harvard Apparatus Regenerative Technology, Inc.
HRGNDrugs in Pipeline
6
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
How HRGN's past catalysts played out
Testosterone
Hip Fracture
LACTIN-V
Bacterial Vaginosis
Folinic Acid
Autism Spectrum Disorder
Theophylline
Pseudohypoparathyroidism
glucagon
Post-bariatric Hypoglycemia
Ezogabine
Amyotrophic Lateral Sclerosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Testosterone | Phase 3 | Hip Fracture | - | - |
LACTIN-V | Phase 2 | Bacterial Vaginosis | - | - |
Folinic Acid | Phase 2 | Autism Spectrum Disorder | - | - |
Theophylline | Phase 2 | Pseudohypoparathyroidism | - | - |
glucagon | Phase 2 | Post-bariatric Hypoglycemia | - | - |
Ezogabine | Phase 2 | Amyotrophic Lateral Sclerosis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Harvard Apparatus Regenerative Technology, Inc.'s drug pipeline?→
CatalystAlert tracks 6 drug candidates in Harvard Apparatus Regenerative Technology, Inc.'s (HRGN) pipeline across Phase 3, Phase 2. Its lead program is Testosterone (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Harvard Apparatus Regenerative Technology, Inc.'s next FDA catalyst?→
Harvard Apparatus Regenerative Technology, Inc.'s (HRGN) next tracked catalyst is a Phase 2 expected December 1, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track HRGN biotech catalysts?→
Add HRGN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Harvard Apparatus Regenerative Technology, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.